Our findings confirm that IF1 could be a novel research target in cholesterol-related disorders and also in SLOS, and could contribute to the general debate on IF1 as a new modulator of cholesterol levels. The gene discussed is ATP5IF1; the disease is Smith-Lemli-Opitz syndrome.